This pair of preprints describe a multi-protein, serum-based assay panel developed using Olink® PEA methodology. Analytical and clinical validation studies from teams at Harvard and Octave bioscience evaluates an 18 protein, serum-based assay, which integrates markers of immune-modulation, neuro-inflammation, myelin biology, and neuro-axonal integrity to predict presence of Gd+ lesions, N/E T2 lesion presence, and active/stable disease status. The authors suggest that this panel provide a more nuanced way to diagnose, monitor, and manage MS patients.
Other Recent Preprints:
Multiscale networks in multiple sclerosis
Dropcite index: 
A Mechanistic Insight into Sources of Error of Visual Working Memory in Multiple Sclerosis
DropCite Index: 
DropCite Index:
Dilated Virchow-Robin Spaces are a Marker for Arterial Disease in Multiple Sclerosis
DropCite Index: 
GEO Data Sets Analysis On Mechanism of Action of IFNβ-1a Treatment in Multiple Sclerosis
DropCite Index:
DropCite Index:
DropCite Index: 
